As per the report, the size of the global dendritic cell cancer vaccines market is forecasted to grow at a robust CAGR from 2019 to 2024.
Human tumours express several protein antigens that can be recognized by T cells; thus, it provides potential targets for cancer therapy. Dendritic cells are rare leukocytes that are uniquely potent in their ability to present antigen to the T cells, according to WHO around 9.6 million people died in the year 2018. Also, about 300000 cases were detected in the children of the age 0 – 19 years. The isolated dendritic cells are loaded with tumour antigen ex vivo. They are administrated as a cellular vaccine and been found to induce protective and therapeutic anti-tumour immunity during the experiment.
MARKET DRIVERS
Growing incidence of cancer across the world is majorly propelling the market growth. Raising funds for the development of new vaccine-related to disease from the public and private organizations is boosting the market growth. The allogeneic dendritic cells are used to create a vaccine for COVID-19. On-going research on the development of vaccines to cure tumour cells is escalating the demand of the market. Increasing disposable income in developed and developing countries is levelling up the growth rate of the market.
MARKET RESTRAINTS
Lack of knowledge over the utilization of vaccines in various forms is slowly degrading the demand of the market. Stringent rules and regulations by the government is also a factor impeding the need of the dendritic cell vaccines market. The shortage of skilled professionals in the research centres is also limiting the growth rate of the market.
RECENT MARKET DEVELOPMENTS
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 to 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 to 2024 |
|
Segments Covered |
By Product Type, End-User and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This market research report on Global Dendritic Cell Cancer Vaccines Market has been segmented based on the product type, end-user and region.
Dendritic Cell Cancer Vaccines Market - By Product Type:
Based on product type, the Provenge was the first DC vaccine which was introduced in the market. So naturally, it follows that it is the market leader and is expected to remain so until the end of the forecast period. It treats melanoma, prostate cancer etc. It was approved by the FDA nearly seven years ago.
Dendritic Cell Cancer Vaccines Market - By End User:
Dendritic Cell Cancer Vaccines Market - By Region:
Regionally, North American captured the highest share in the global market. The United States leads the market in North America. Europe is not far behind and is expected to close in on the North American market in the forecast mentioned above period. The UK is the market leader in this region.
The Asia Pacific will continue its high growth spurt until 2024. Booming economies of India and China are spearheading this spectacular growth. Latin America and MEA continue to lag and will remain the least attractive markets all through the forecast period.
TOP COMPANIES IN THE MARKET
Key market participants leading the global dendritic cell cancer vaccines market profiled in the report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene and Merck & Co.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 CreaVax
5.1.3 Sipuleucel-T (Provenge)
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2 End User
5.2.1 Introduction
5.2.2 Pediatrics
5.2.3 Adults
5.2.4 Y-o-Y Growth Analysis, By End User
5.2.5 Market Attractiveness Analysis, By End User
5.2.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By End User
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 3M Company
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Activarti
8.3 Argos Therapeutics
8.4 Batavia Bioservices
8.5 Bellicum Pharmaceuticals
8.6 Creagene
8.7 DanDrit Biotech
8.8 DCPrime
8.9 Sanpower Corporation (Dendreon Corporation)
8.10 Elios Therapeutics
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
